Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas
Thibault Kervarrec, Anne Tallet, Elodie Miquelestorena-Standley, Roland Houben, David Schrama, Thilo Gambichler, Patricia Berthon, Yannick Le Corre, Ewa Hainaut-Wierzbicka, Francois Aubin, Guido Bens, Flore Tabareau-Delalande, Nathalie Beneton, Gaëlle Fromont, Flavie Arbion, Emmanuelle Leteurtre, Antoine Touzé, Mahtab Samimi, Serge Guyétant, Thibault Kervarrec, Anne Tallet, Elodie Miquelestorena-Standley, Roland Houben, David Schrama, Thilo Gambichler, Patricia Berthon, Yannick Le Corre, Ewa Hainaut-Wierzbicka, Francois Aubin, Guido Bens, Flore Tabareau-Delalande, Nathalie Beneton, Gaëlle Fromont, Flavie Arbion, Emmanuelle Leteurtre, Antoine Touzé, Mahtab Samimi, Serge Guyétant
Abstract
Merkel cell carcinoma is a rare neuroendocrine carcinoma of the skin mostly induced by Merkel cell polyomavirus integration. Cytokeratin 20 (CK20) positivity is currently used to distinguish Merkel cell carcinomas from other neuroendocrine carcinomas. However, this distinction may be challenging in CK20-negative cases and in cases without a primary skin tumor. The objectives of this study were first to evaluate the diagnostic accuracy of previously described markers for the diagnosis of Merkel cell carcinoma and second to validate these markers in the setting of difficult-to-diagnose Merkel cell carcinoma variants. In a preliminary set (n = 30), we assessed optimal immunohistochemical patterns (CK20, thyroid transcription factor 1 [TTF-1], atonal homolog 1 [ATOH1], neurofilament [NF], special AT-rich sequence-binding protein 2 [SATB2], paired box protein 5, terminal desoxynucleotidyl transferase, CD99, mucin 1, and Merkel cell polyomavirus-large T antigen) and Merkel cell polyomavirus load thresholds (real-time PCR). The diagnostic accuracy of each marker was then assessed in a validation set of 103 Merkel cell carcinomas (9 CK20-negative cases and 15 cases without a primary skin tumor) and 70 extracutaneous neuroendocrine carcinoma cases. The most discriminant markers for a diagnosis of Merkel cell carcinoma were SATB2, NF expression, and Merkel cell polyomavirus DNA detection (positive likelihood ratios: 36.6, 44.4, and 28.2, respectively). Regarding Merkel cell carcinoma variants, cases without a primary skin tumor retained a similar immunohistochemical profile and CK20-negative tumors displayed a different profile (decrease frequency of NF and SATB2 expression), but Merkel cell polyomavirus DNA remained detected (78% of cases by qPCR). Moreover, 8/9 (89%) CK20-negative Merkel cell carcinoma cases but only 3/61 (5%) CK20-negative extracutaneous neuroendocrine cases were positive for at least one of these markers. In conclusion, detection of SATB2 and NF expression and Merkel cell polyomavirus DNA helps distinguish between Merkel cell carcinoma classical and variant cases and extracutaneous neuroendocrine carcinomas.
Source: PubMed